CN111588816A

CN111588816A - Medicine composition for clearing lung-heat chemical fibers and application thereof

Info

Publication number: CN111588816A
Application number: CN202010416593.5A
Authority: CN
Inventors: 张莹雯
Original assignee: Zhongnan Hospital of Wuhan University
Current assignee: Zhongnan Hospital of Wuhan University
Priority date: 2020-05-15
Filing date: 2020-05-15
Publication date: 2020-08-28
Also published as: WO2021227614A1

Abstract

The invention discloses a pharmaceutical composition for clearing lung-heat chemical fibers and application thereof, wherein the composition comprises the following components in parts by weight: 6-10 parts of raw ephedra, 3-10 parts of liquorice, 9-12 parts of almond, 15-20 parts of gypsum, 6-12 parts of wrinkled gianthyssop herb, 6-12 parts of tsaoko amomum fruit, 8-12 parts of rhizoma pinellinae praeparata, 3-6 parts of raw rhubarb, 10-15 parts of radix pseudostellariae, 10-15 parts of semen lepidii, 10-15 parts of red paeony root, 10-12 parts of betel nut, 10-15 parts of immature bitter orange, 15-20 parts of stiff silkworm, 15-20 parts of thunberg fritillary bulb, 15-20 parts of loofah sponge and 8-12 parts of reed rhizome. The invention applies specific compatible Chinese herbal medicines with the efficacies of clearing lung and expelling toxin, strengthening spleen and relieving asthma, reducing phlegm and resolving masses, and removing blood stasis and dredging collaterals to novel patients with severe coronary pneumonia, mainly plays the roles of relieving cough and asthma, promoting lung infection and absorption and disappearance of exudative focuses, reducing the actual change range and density, preventing pulmonary fibrosis and having obvious curative effect.

Description

Medicine composition for clearing lung-heat chemical fibers and application thereof

Technical Field

The invention relates to a traditional Chinese medicine composition, in particular to a medicine composition for clearing lung-heat chemical fibers and application thereof.

Background

Pulmonary fibrosis is a common pathological change of various chronic lung diseases, can be caused by various factors such as smoking, virus infection, environmental pollution, genetic susceptibility, medicaments and the like, and is mainly characterized in that the pulmonary interstitial inflammatory exudation causes excessive proliferation of fibroblasts and deposition of collagen in the lung, the pulmonary alveolar structure is damaged, and the lung function is progressively reduced. Mild pulmonary fibrosis is mainly manifested by labored dyspnea, and progressive dyspnea is developed in severe cases, and patients in late stage die due to exhaustion of cardiopulmonary function, which seriously affects the quality of life of the patients. At present, the pathogenesis of pulmonary fibrosis is not clear, effective treatment medicines are also lacking clinically, and the prognosis is poor.

The novel coronavirus pneumonia (COVID-19) is pneumonia caused by infection of a novel coronavirus (2019-nCOV), based on the prior research, SARS-COV and MERS-COV severe infection patients are considered to cause severe pulmonary fibrosis due to a large amount of interstitial pulmonary inflammatory exudation in an acute stage, and the anatomy of patients with COVID-19 death finds that the main risk factor is that mucus in small airways forms phlegm embolism, the airway is blocked, and the lung interstitial fibrosis is not caused. However, the pulmonary imaging of a large number of patients with severe and critical COVID-19 suggests obvious pulmonary interstitial fibrosis, which indicates that 2019-nCOV infection may also cause pulmonary fibrosis change and cause irreversible injury. Although glucocorticoid treatment, oxygen treatment, blood purification and the like are proved to inhibit lung inflammatory reaction and reduce fatality rate, no effective evidence exists whether pulmonary fibrosis can be improved. In addition, nintedanib and pirfenidone have been approved by the Food and Drug Administration (FDA) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis, but these 2 drugs also only slow the progression of pulmonary fibrosis, do not reverse the pathological changes of fibrosis, and do not completely prevent the decline of pulmonary function in patients.

Therefore, the development of a traditional Chinese medicine with the effects of expelling toxin, relieving asthma, removing blood stasis and dredging collaterals and adjuvant therapy are urgently needed to improve the severe cure rate.

Disclosure of Invention

The invention aims to solve the problem of pulmonary fibrosis, provides a traditional Chinese medicine composition for lung-clearing chemical fibers, has the effects of expelling toxin, relieving asthma, removing blood stasis and dredging collaterals, solves the problem of pulmonary fibrosis, and is particularly suitable for treating novel severe patients with coronary pneumonia.

In order to achieve the purpose, the invention provides a pharmaceutical composition for clearing lung-heat chemical fibers, which comprises the following components in parts by weight: 6-10 parts of raw ephedra, 3-10 parts of liquorice, 9-12 parts of almond, 15-20 parts of gypsum, 6-12 parts of wrinkled gianthyssop herb, 6-12 parts of tsaoko amomum fruit, 8-12 parts of rhizoma pinellinae praeparata, 3-6 parts of raw rhubarb, 10-15 parts of radix pseudostellariae, 10-15 parts of semen lepidii, 10-15 parts of red paeony root, 10-12 parts of betel nut, 10-15 parts of immature bitter orange, 15-20 parts of stiff silkworm, 15-20 parts of thunberg fritillary bulb, 15-20 parts of loofah sponge and 8-12 parts of reed rhizome.

Preferably, the gypsum is pre-fried.

Preferably, the amount of the raw gypsum is 1.5-2.5 times of that of the raw ephedra herb by mass ratio.

The invention also provides application of the pharmaceutical composition for clearing away the lung-heat chemical fibers in preparation of a medicine for clearing away the lung-heat chemical fibers.

Preferably, the medicament is for use against a novel coronavirus.

Preferably, the medicament is a preparation prepared by taking the medicinal composition as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.

Preferably, the active ingredient comprises: the medicinal powder, the water extract or the organic solvent extract of the medicinal composition.

Preferably, the preparation is powder, tablets, paste, granules, capsules or oral liquid.

The formula of the pharmaceutical composition of the invention follows the principle of monarch, minister, assistant and guide: gypsum Fibrosum, herba Ephedrae, Bulbus Fritillariae Thunbergii, Bombyx Batryticatus as principal drug, semen Armeniacae amarum, fructus Tsaoko, rhizoma Pinelliae Preparata, radix Pseudostellariae, radix Paeoniae Rubra, retinervus Luffae fructus as ministerial drug, herba Agastaches, radix et rhizoma Rhei, semen Lepidii, Arecae semen, fructus Aurantii Immaturus, and rhizoma Phragmitis as adjuvant drug, and Glycyrrhrizae radix as messenger drug.

The pharmaceutical composition of the invention has the following compatibility:

the ephedra herb is matched with the gypsum, the ephedra herb is pungent and slightly bitter in taste and warm in nature, enters lung and bladder channels, sweats to release exterior, ventilates the lung to relieve asthma, and induces diuresis to alleviate edema; gypsum, Gypsum Fibrosum, pungent and sweet in flavor and cold in nature, enters lung and stomach meridians and is used for purging fire and heat in lung and stomach. The traditional Chinese medicine composition has the effects of mutually matching the two, namely pungent-warm property, pungent-cold property which is higher than pungent-warm property, 1.5-2 times of gypsum amount as heavy dose as pungent-cold property, and has the effects of freeing lung, benefiting qi and relieving exterior syndrome for the symptoms of lung and stomach heat stagnation and qi and blood internal stagnation, and the gypsum has the effects of clearing lung and stomach heat, clearing heat evil and relieving cough and asthma, and is mainly used for treating fever and cough and asthma caused by heat stagnation in lung and lung failure.

Zhe Bei mu is cold in nature and bitter in taste, enters lung meridian and is indicated for cough due to phlegm-heat and pulmonary abscess. Zhe Bei mu, Ma Huang and Shi Gao achieve the actions of clearing heat, resolving hard mass, resolving phlegm and stopping cough. Ting Li Zi is cold in nature, pungent and bitter in flavor, entering lung and large intestine meridians, and has the action of purging lung and relieving asthma. The almond kernel, semen armeniacae amarum, semen lepidii, acts as a minister to disperse and promote lung qi, and assists the ephedra herb to relieve cough and asthma. According to the "Zhengyuan diet" (for treating cold syndrome of Taiyin alone prevailing); caoguo is warm in nature and pungent in flavor, enters spleen and stomach meridians, and has the effects of expelling cold, removing miasma, checking malaria, eliminating turbid pathogen and eliminating phlegm. Fa ban Xia is pungent and warm in flavor and warm in property, entering spleen, stomach and lung meridians, and good at drying dampness and resolving phlegm, so it is indicated for cough and dyspnea due to excessive phlegm. Huoxiang is slightly warm in nature and pungent in flavor, enters spleen, stomach and lung meridians, is good at resolving dampness with aromatics, regulating the middle energizer and arresting vomiting, and is indicated for damp obstruction of middle energizer, vomiting, summer-heat dampness or damp-warm syndrome, fullness and distention in chest and stomach and nausea. Bing Lang is warm in nature, bitter and pungent in flavor, enters stomach and large intestine meridians, has the effects of promoting qi circulation and removing food retention, and checking malaria, and is used for food retention and phlegm stagnation. The bitter orange is slightly cold in nature, bitter and pungent in taste, enters spleen, stomach and large intestine channels, has the effects of breaking qi and resolving phlegm, dispersing food retention and relieving stuffiness, is used for food retention and phlegm stagnation and fullness and distention in chest and abdomen and distending pain, and is often used with betel nut with similar effect. The fructus Tsaoko is combined with rhizoma Pinelliae Preparata, herba Agastaches, Arecae semen, and fructus Aurantii Immaturus, and has effects of invigorating spleen, eliminating dampness, eliminating turbid pathogen, and eliminating phlegm stagnation. Bombyx Batryticatus is salty, pungent and neutral, and enters liver, lung and stomach meridians. Luffa vegetable sponge is sweet in flavor and cold in nature, enters lung meridian, and is good at dispelling wind and resolving phlegm, dredging collaterals and removing arthralgia. Radix Pseudostellariae is sweet and slightly bitter in taste and slightly cold in nature, and has effects of invigorating qi, nourishing blood, and invigorating spleen. Red peony root, a little cold in nature and bitter in taste, enters liver meridian and excels in dissipating blood stasis and activating blood circulation. The stiff silkworm is combined with thunberg fritillary bulb, loofah sponge, radix pseudostellariae and red paeony root, and has the effects of reducing phlegm and resolving masses, tonifying qi and activating blood, dissolving stasis and dredging collaterals, promoting absorption and disappearance of focus infected and exudated from lung, reducing actual change range and density and preventing pulmonary fibrosis. Rhizoma phragmitis is cold in nature and sweet in taste, enters lung and stomach meridians, has the effects of clearing heat and relieving restlessness, and is used for cough and pharyngalgia. Raw rhubarb is bitter in taste, enters spleen, stomach, large intestine and other channels, is good at purging heat-toxin, breaking accumulation and removing blood stasis, and is used for clearing fu-organs and reducing lung qi to stop cough and asthma according to the theory that lung and large intestine are exterior and interior. Licorice root, radix Glycyrrhizae is sweet and neutral, and has the actions of regulating spleen, stomach and lung meridians, clearing heat and removing toxicity, relieving cough, regulating the middle warmer and relieving urgency, and harmonizing the effects of the other drugs.

The traditional Chinese medicine composition has the effects of clearing lung, expelling toxin, strengthening spleen, relieving asthma, reducing phlegm, resolving masses, removing blood stasis, dredging collaterals, promoting absorption of lung infection and exudation and improving lung function by combining the medicines. Wherein the medicines for preventing pulmonary fibrosis are Gypsum Fibrosum, herba Ephedrae, Bulbus Fritillariae Thunbergii, and Bombyx Batryticatus.

The invention firstly uses the specific compatible Chinese herbal medicines with the efficacies of clearing lung, expelling toxin, strengthening spleen, relieving asthma, reducing phlegm, resolving masses, removing blood stasis and dredging collaterals for the novel patients with severe coronary pneumonia, and particularly has unexpected technical effects of preventing pulmonary fibrosis by matching thunberg fritillary bulb, stiff silkworm, red paeony root and loofah sponge with the efficacies of reducing phlegm, resolving masses, removing blood stasis and dredging collaterals. The pharmaceutical composition provided by the invention mainly has the effects of relieving cough and asthma, promoting absorption and disappearance of focus infected and exudated by lung, reducing actual change range and density, preventing pulmonary fibrosis, and is particularly suitable for severe patients with new coronavirus.

Detailed Description

The invention provides a pharmaceutical composition for clearing lung-heat chemical fibers, which comprises the following components in parts by weight: 6-10 parts of raw ephedra, 3-10 parts of liquorice, 9-12 parts of almond, 15-20 parts of gypsum, 6-12 parts of wrinkled gianthyssop herb, 6-12 parts of tsaoko amomum fruit, 8-12 parts of rhizoma pinellinae praeparata, 3-6 parts of raw rhubarb, 10-15 parts of radix pseudostellariae, 10-15 parts of semen lepidii, 10-15 parts of red paeony root, 10-12 parts of betel nut, 10-15 parts of immature bitter orange, 15-20 parts of stiff silkworm, 15-20 parts of thunberg fritillary bulb, 15-20 parts of loofah sponge and 8-12 parts of reed rhizome.

In practice, the pharmaceutical composition is properly increased or decreased within the scope of the formula according to the compatibility principle and different symptom manifestations or symptom degrees.

In the following examples, gypsum was previously decocted. The pre-decoction is carried out by conventional decocting method for Chinese medicinal materials, such as decocting with water for 20 min.

Example 1

Weighing 6g of raw ephedra herb, 3g of liquorice, 9g of almond, 15g of gypsum, 6g of wrinkled gianthyssop herb, 6g of tsaoko amomum fruit, 8g of rhizoma pinellinae praeparata, 3g of raw rhubarb, 10g of radix pseudostellariae, 10g of semen lepidii, 10g of red paeony root, 10g of betel nut, 10g of immature bitter orange, 15g of stiff silkworm, 15g of thunberg fritillary bulb, 15g of loofah sponge and 8g of reed rhizome respectively, adding about 2L of water for decoction, and decocting to 200ml for later.

Example 2

Weighing 10g of raw ephedra herb, 10g of liquorice, 12g of almond, 20g of gypsum, 12g of wrinkled gianthyssop herb, 12g of tsaoko amomum fruit, 12g of rhizoma pinellinae praeparata, 6g of raw rhubarb, 15g of radix pseudostellariae, 15g of semen lepidii, 15g of red paeony root, 12g of betel nut, 15g of immature bitter orange, 20g of stiff silkworm, 20g of thunberg fritillary bulb, 20g of loofah sponge and 12g of reed rhizome respectively, adding about 2L of water for decoction, and decocting to 200ml for later.

Example 3

Weighing raw ephedra herb 12g, licorice root 6g, almond 10g, gypsum 18g, wrinkled gianthyssop 9g, tsaoko amomum fruit 9g, rhizoma pinellinae praeparata 10g, raw rhubarb 4g, pseudostellaria root 12g, lepidium seed 13g, red peony root 12g, areca nut 11g, immature bitter orange 12g, stiff silkworm 18g, thunberg fritillary bulb 18g, loofah sponge 17g and reed rhizome 10g respectively, adding about 2L of water for decocting, and decocting to 200ml for later use.

All the patients in 86 groups take the decoction (marked as traditional Chinese medicine lung-clearing chemical fiber decoction) of the pharmaceutical composition for clearing lung-heat chemical fibers orally, and the treatment course is 7 days.

The administration method comprises the following steps: decocting with water, 2 times daily, 1 bag (200ml) each time, and orally or nasally feeding.

The evaluation criteria of the syndrome curative effect (the traditional Chinese medicine syndrome scoring table is shown in table 1):

the clinical recovery: the main symptoms and physical signs disappear, and the curative effect index is more than or equal to 95 percent.

Secondly, effect is displayed: the main symptoms and physical signs are obviously improved, and the curative effect index is more than or equal to 70 percent and less than 95 percent.

③ effective: the main symptoms and physical signs are obviously improved, and the curative effect index is more than or equal to 30 percent and less than 70 percent.

Fourthly, invalidation: the main symptoms and physical signs are not obviously improved or even aggravated, and the curative effect index is less than 30 percent.

Efficacy index ═ integration before treatment-integration after treatment)/integration before treatment ] × 100%.

Table 1: chinese medicine syndrome scoring table

The results are as follows:

1. evaluation of therapeutic Effect

By 7 days 4 months in 2020, 86 patients were discharged, none of them turned into critical illness and no death occurred. As shown in table 2, the total effective rate was 94.18%, and there was no recurrence in all patients within 4 weeks of follow-up.

Table 2: effective rate of lung-clearing and chemical fiber decoction

Total number of cases	Recovery method	Show effect	Is effective	Invalidation	Total effective rate
						86	18(20.93％)	36(41.86％)	27(31.39％)	5(5.81％)	81(94.18％)

2. Symptom improvement in traditional Chinese medicine

After 7 days of treatment, the scores of the symptoms of fever, hypodynamia, cough, anorexia, shortness of breath and soreness of limbs of the patients are all lower than that before treatment (P <0.05), as shown in Table 3. Among them, the improvement of hypodynamia, anorexia and shortness of breath is most obvious.

Table 3: integral comparison of Chinese medicine syndrome before and after treatment

In Table 3, symbols "^*"represents comparison P <0.05 before treatment.

3. Improvement of novel coronavirus nucleic acid negative-turning time and lung CT

The time for transferring the novel coronavirus nucleic acid to negative is 6-13 days, and the average time is 8.5 days. CT shows that the lung focus is mainly formed by combining and consolidating the lung vitreous opacities (GGO) and GGO before treatment, and most of the lung lesions are simultaneously affected by a plurality of lung lobes of two lungs. The lung CT was reviewed within 2 weeks after the administration of the drug, and the results showed that 79 (91.86%) patients had more advanced lung lesion absorption, 7 of which were completely absorbed and 72 of which were partially absorbed. Mainly manifested by the reduction of the number of lesions, the reduction of the range of actual change and the reduction of the density. The lung injury score was decreased compared to before treatment, and the difference was statistically significant.

Clinical practices prove that the pharmaceutical composition has clinical effects of reversing severe disease progression, reducing fatality rate and improving cure rate for treating severe patients.

The pharmaceutical composition for clearing lung-heat chemical fibers provided by the invention is suitable for treating the clearing lung-heat chemical fibers, and is particularly suitable for treating severe patients infected with novel coronavirus.

In some embodiments, the pharmaceutical composition is used as an active ingredient, and pharmaceutically acceptable adjuvants or auxiliary ingredients are added to prepare a preparation, wherein the preparation can be powder, tablets, paste, granules, capsules or oral liquid.

In some embodiments, the active ingredient comprises: the medicinal powder, water extract or organic solvent extract of the medicinal composition is ethanol.

In conclusion, the lung-clearing chemical fiber pharmaceutical composition provided by the invention is used for improving pulmonary fibrosis symptoms of novel patients with severe coronary pneumonia by using specific compatible Chinese herbal medicines with the efficacies of clearing lung and expelling toxin, strengthening spleen and relieving asthma, reducing phlegm and resolving masses, and removing blood stasis and dredging collaterals, and particularly, thunberg fritillary bulb, stiff silkworm, red paeony root and loofah sponge with the efficacies of reducing phlegm and resolving masses, removing blood stasis and dredging collaterals are used in a matching manner to prevent pulmonary fibrosis, so that unexpected technical effects are achieved, and the lung-clearing chemical fiber pharmaceutical composition has a good application prospect.

While the present invention has been described in detail with reference to the preferred embodiments, it should be understood that the above description should not be taken as limiting the invention. Various modifications and alterations to this invention will become apparent to those skilled in the art upon reading the foregoing description. Accordingly, the scope of the invention should be determined from the following claims.

Claims

1. The pharmaceutical composition for clearing lung-heat chemical fibers is characterized by comprising the following components in parts by weight: 6-10 parts of raw ephedra, 3-10 parts of liquorice, 9-12 parts of almond, 15-20 parts of gypsum, 6-12 parts of wrinkled gianthyssop herb, 6-12 parts of tsaoko amomum fruit, 8-12 parts of rhizoma pinellinae praeparata, 3-6 parts of raw rhubarb, 10-15 parts of radix pseudostellariae, 10-15 parts of semen lepidii, 10-15 parts of red paeony root, 10-12 parts of betel nut, 10-15 parts of immature bitter orange, 15-20 parts of stiff silkworm, 15-20 parts of thunberg fritillary bulb, 15-20 parts of loofah sponge and 8-12 parts of reed rhizome.

2. The pharmaceutical composition for clearing lung-heat chemical fibers as claimed in claim 1, wherein the gypsum is decocted in advance.

3. The pharmaceutical composition for clearing lung-heat chemical fibers as claimed in claim 1, wherein the amount of the raw gypsum is 1.5-2.5 times of that of the raw ephedra herb in terms of mass ratio.

4. Use of the pharmaceutical composition for lung-clearing chemical fibers according to claim 1 in preparation of a medicament for lung-clearing chemical fibers.

5. Use according to claim 4, wherein the medicament is against a novel coronavirus.

6. The use according to claim 4, wherein the medicament is a preparation prepared by using the pharmaceutical composition according to claim 1 as an active ingredient and matching with pharmaceutically acceptable auxiliary materials or auxiliary ingredients.

7. The use according to claim 6, wherein the active ingredient comprises: the medicinal powder, the water extract or the organic solvent extract of the medicinal composition.

8. The use of claim 6, wherein the formulation is a powder, tablet, paste, granule, capsule or oral liquid.